Similarly, Lasso et al. detected an increased serum level of TNF-α and IL-6 and a decrease of IL-17 and IL-4 in in vivo melanoma mouse models treated with the P2Et prophylactic plus therapeutic protocol, while the breast cancer in vivo model did not show changes in cytokines production [91], strongly hinting at different immunoregulatory systems operating in mice (melanoma) and human (breast cancer) tumor microenvironment. The gene discussed is IL17A; the disease is breast carcinoma.